Drugs / RP7214
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04680429 | Dec 2020 → Jul 2021 | — | Rhizen Pharmaceuticals SA | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05246384 | Jan 2023 → Dec 2024 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Rhizen Pharmaceuticals SA | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05007236 | Sep 2021 → Mar 2022 | COVID-19 | Rhizen Pharmaceuticals SA | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP7214 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05246384 ↗ |
| Action | Inhibit | “RP7214 is a potent and selective inhibitor of human DHODH” PMID 36217901 ↗ Nov 2022 |
| Route | Oral | “single and multiple ascending oral doses of RP7214” NCT04680429 ↗ |
| Target | DHODH | “RP7214 is a potent and selective inhibitor of human DHODH” PMID 36217901 ↗ Nov 2022 |